Reuters logo
BRIEF-Catalyst Pharmaceuticals provides update on the status of its Firdapse development activities
August 30, 2017 / 12:20 PM / a month ago

BRIEF-Catalyst Pharmaceuticals provides update on the status of its Firdapse development activities

Aug 30 (Reuters) - Catalyst Pharmaceuticals Inc

* Catalyst Pharmaceuticals provides update on the status of its Firdapse development activities

* Catalyst Pharmaceuticals Inc - ‍expected NDA submission for Firdapse moves from end of 2017 to Q1 2018​

* Catalyst Pharmaceuticals Inc - dosing of first patients in phase 3 trial in early 2018​

* Catalyst Pharmaceuticals Inc - expects to complete enrollment “shortly”, to announce top-line results from confirmatory phase 3 study (lms-003) in q4 this year​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below